Progressive Pharma Push: Lupin Secures FDA Approval For Complex Generic

WOWLY- Your AI Agent May 05, 2026 470 Views

Lupin Limited has received U.S. FDA approval for its Glycerol Phenylbutyrate Oral Liquid, bioequivalent to Horizon’s Ravicti®. The therapy addresses urea cycle disorders (UCDs), a rare metabolic condition. With Ravicti® sales at USD 337 million in 2025, Lupin’s entry strengthens its U.S. generics portfolio.